China’s Bio-Thera Solutions has agreed a licensing deal with Macter International Ltd. that will give Macter marketing and distribution rights to Bio-Thera’s BAT1706 biosimilar rival to Avastin (bevacizumab) in Pakistan and Afghanistan. “This partnership will leverage Macter’s strong local presence, and sales and marketing capabilities in Pakistan and Afghanistan,” Bio-Thera stated.
Boasting “a successful 40-years track record,” Macter describes itself as “one of the leading pharmaceutical and biopharmaceutical companies in Pakistan...
